These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27636543)

  • 1. Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study.
    Obert D; Helms G; Sättler MB; Jung K; Kretzschmar B; Bähr M; Dechent P; Diem R; Hein K
    PLoS One; 2016; 11(9):e0162583. PubMed ID: 27636543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis.
    Chard DT; Griffin CM; McLean MA; Kapeller P; Kapoor R; Thompson AJ; Miller DH
    Brain; 2002 Oct; 125(Pt 10):2342-52. PubMed ID: 12244090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study.
    Tiberio M; Chard DT; Altmann DR; Davies G; Griffin CM; McLean MA; Rashid W; Sastre-Garriga J; Thompson AJ; Miller DH
    J Neurol; 2006 Feb; 253(2):224-30. PubMed ID: 16307201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.
    John NA; Solanky BS; De Angelis F; Parker RA; Weir CJ; Stutters J; Carrasco FP; Schneider T; Doshi A; Calvi A; Williams T; Plantone D; Monteverdi A; MacManus D; Marshall I; Barkhof F; Gandini Wheeler-Kingshott CAM; Chataway J;
    J Magn Reson Imaging; 2024 Jun; 59(6):2192-2201. PubMed ID: 37787109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis.
    Sastre-Garriga J; Ingle GT; Chard DT; Ramió-Torrentà L; McLean MA; Miller DH; Thompson AJ
    Arch Neurol; 2005 Apr; 62(4):569-73. PubMed ID: 15824254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis.
    Tourbah A; Stievenart JL; Gout O; Fontaine B; Liblau R; Lubetzki C; Cabanis EA; Lyon-Caen O
    Neurology; 1999 Sep; 53(5):1091-7. PubMed ID: 10496272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothalamic damage in multiple sclerosis correlates with disease activity, disability, depression, and fatigue.
    Kantorová E; Poláček H; Bittšanský M; Baranovičová E; Hnilicová P; Čierny D; Sivák Š; Nosáľ V; Zeleňák K; Kurča E
    Neurol Res; 2017 Apr; 39(4):323-330. PubMed ID: 28191860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroinflammatory component of gray matter pathology in multiple sclerosis.
    Herranz E; Giannì C; Louapre C; Treaba CA; Govindarajan ST; Ouellette R; Loggia ML; Sloane JA; Madigan N; Izquierdo-Garcia D; Ward N; Mangeat G; Granberg T; Klawiter EC; Catana C; Hooker JM; Taylor N; Ionete C; Kinkel RP; Mainero C
    Ann Neurol; 2016 Nov; 80(5):776-790. PubMed ID: 27686563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.
    Suhy J; Rooney WD; Goodkin DE; Capizzano AA; Soher BJ; Maudsley AA; Waubant E; Andersson PB; Weiner MW
    Mult Scler; 2000 Jun; 6(3):148-55. PubMed ID: 10871825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter.
    Vrenken H; Barkhof F; Uitdehaag BM; Castelijns JA; Polman CH; Pouwels PJ
    Magn Reson Med; 2005 Feb; 53(2):256-66. PubMed ID: 15678547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings.
    Sijens PE; Mostert JP; Oudkerk M; De Keyser J
    Eur Radiol; 2006 Feb; 16(2):489-95. PubMed ID: 16028056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSI.
    Tur C; Wheeler-Kingshott CA; Altmann DR; Miller DH; Thompson AJ; Ciccarelli O
    Hum Brain Mapp; 2014 Mar; 35(3):993-1003. PubMed ID: 23281189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain
    Donadieu M; Le Fur Y; Maarouf A; Gherib S; Ridley B; Pini L; Rapacchi S; Confort-Gouny S; Guye M; Schad LR; Maudsley AA; Pelletier J; Audoin B; Zaaraoui W; Ranjeva JP
    Mult Scler; 2019 Jan; 25(1):39-47. PubMed ID: 29064346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proton magnetic-resonance spectroscopy in remitting and secondary-progressive multiple sclerosis].
    Pozdniakov AV; Tiutin LA; Bisaga GN; Odinak MM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(4):36-9. PubMed ID: 11490432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton MR spectroscopy of lesion evolution in multiple sclerosis: Steady-state metabolism and its relationship to conventional imaging.
    Kirov II; Liu S; Tal A; Wu WE; Davitz MS; Babb JS; Rusinek H; Herbert J; Gonen O
    Hum Brain Mapp; 2017 Aug; 38(8):4047-4063. PubMed ID: 28523763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations.
    Schubert F; Seifert F; Elster C; Link A; Walzel M; Mientus S; Haas J; Rinneberg H
    MAGMA; 2002 Jun; 14(3):213-22. PubMed ID: 12098564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.
    Adalsteinsson E; Langer-Gould A; Homer RJ; Rao A; Sullivan EV; Lima CA; Pfefferbaum A; Atlas SW
    AJNR Am J Neuroradiol; 2003; 24(10):1941-5. PubMed ID: 14625214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Cortical Lesions With Regional Glutamate, GABA,
    Madsen MA; Považan M; Wiggermann V; Lundell H; Blinkenberg M; Romme Christensen J; Sellebjerg F; Siebner HR
    Neurology; 2024 Jul; 103(1):e209543. PubMed ID: 38870443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An In-vivo 1H-MRS short-echo time technique at 7T: Quantification of metabolites in chronic multiple sclerosis and neuromyelitis optica brain lesions and normal appearing brain tissue.
    Tackley G; Kong Y; Minne R; Messina S; Winkler A; Cavey A; Everett R; DeLuca GC; Weir A; Craner M; Tracey I; Palace J; Stagg CJ; Emir U
    Neuroimage; 2021 Sep; 238():118225. PubMed ID: 34062267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis.
    Wiebenga OT; Klauser AM; Schoonheim MM; Nagtegaal GJ; Steenwijk MD; van Rossum JA; Polman CH; Barkhof F; Pouwels PJ; Geurts JJ
    AJNR Am J Neuroradiol; 2015 Jun; 36(6):1116-23. PubMed ID: 25742985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.